Clinical trial
Novel Adjuvants for Peptide-Based Melanoma Vaccines
NCT00028431 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00028431 |
|---|---|
| Title | Novel Adjuvants for Peptide-Based Melanoma Vaccines |
| Official title | An Open Label Study of MDX-CTLA4 in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 in the Treatment of Patients With Resected Stage III or IV Melanoma |
| Lead sponsor | University of Southern California, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | MDX-CTLA4 Antibody, Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine |
| Enrollment | 19 |
| Start date | Aug 1, 2001 |
| Primary completion | Jan 1, 2003 |
| Completion | Jun 1, 2005 |
| First posted | Jan 9, 2002 |
| Last update posted | May 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: